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A B S T R A C T   
In resected non-small cell lung cancer (NSCLC), postsurgical recurrence is the major factor affecting long-term 
survival. The identification of biomarkers in extracellular vesicles (EV) obtained from serial blood samples 
after surgery could enhance early detection of relapse and improve NSCLC outcome. Since EV cargo contains 
long non-coding RNAs (lncRNAs), we aimed to analyze whether the oncogenic lncRNA HOTTIP, which higher 
expression in tumor tissue was related to worse outcome in NSCLC, could be detected in EV from NSCLC patients 
and serve as recurrence biomarker. After purification of EVs by ultracentrifugation in 52 serial samples from 18 
NSCLC patients, RNA was isolated and HOTTIP was quantified by Real time PCR. We observed that patients that 
relapsed after surgery displayed increased postsurgical EV HOTTIP levels in comparison with presurgical levels. 
In the relapsed patients with several samples available between surgery and relapse, we observed an increment in 
the EV HOTTIP levels when approaching to relapse, which indicated its potential utility for monitoring disease 
recurrence. When we focused in EV HOTTIP levels in the first post-surgical sample, we observed that the 
detection of an increment of the expression levels in comparison to presurgical sample, predicted recurrence with 
high sensitivity (85.7%) and specificity (90.9%) and that patients had shorter time to relapse and shorter overall 
survival. In conclusion, our pilot study showed that EV HOTTIP is a potential biomarker for monitoring disease 
recurrence after surgery in NSCLC.   
Introduction 
The GLOBOCAN2020 reported that lung cancer accounts for 11.4% 
of total cancer diagnoses and it is still the leading cause of death due to 
oncological disease in both sexes [1]. Non-small cell lung cancer 
(NSCLC) is the most frequent type (85% of cases) and is divided mainly 
into two histological groups, adenocarcinoma and squamous cell carci-
noma [2]. The treatment of patients diagnosed with NSCLC depends on 
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canals.serrat@ub.edu (J. Canals), tdiaz@ub.edu (T. Díaz), lmolins@clinic.cat (L. Molins), dmartin1@clinic.cat (D. Martinez), jrmoises@clinic.cat (J. Moisés), 
dsanche1@clinic.cat (D. Sánchez), mboada@clinic.cat (M. Boada), macostapl@ub.edu (M. Acosta-Plasencia), ccrosifo7@alumnes.ub.edu (C. Cros-Font), 
mmonzo@ub.edu (M. Monzo), anavarroponz@ub.edu (A. Navarro).  
Contents lists available at ScienceDirect 
Translational Oncology 
journal homepage: www.elsevier.com/locate/tranon 
https://doi.org/10.1016/j.tranon.2021.101144 
Received 28 April 2021; Received in revised form 18 May 2021; Accepted 29 May 2021   
Translational Oncology 14 (2021) 101144
2
the stage of the disease, and in the case of patients clinically diagnosed 
with stage I-II, the first therapeutical option is usually the surgical 
resection of the tumor. Although resected patients are considered 
disease-free after surgery, its prognosis is still very unfavorable with a 
5-year survival of 60–80% [3–5]due to high relapse rates of around 40% 
[6]. Therefore it is crucial to find prognostic biomarkers to detect pa-
tients at high risk of relapse after surgery. 
Prognostic biomarkers to classify patients into risk groups have been 
evaluated by means of tumor tissue analysis [7] and by analyzing the 
patient’s blood, the so-called liquid biopsy [8,9] that includes between 
others the study of circulating tumor cells, the circulating free 
DNA/RNA or more recently the study of extracellular vesicles (EV) [10]. 
Small EV are spherical structures of 30–150 nanometers (nm), con-
sisting of a bilipid membrane with various proteins attached. Inside the 
small EV group we find exosomes, which origin is associated to muti-
vesicular bodies [11]. Exosomes are involved in several biological 
functions, including cross-talk between cells, tumorigenesis, drug 
resistance, angiogenesis promotion and metastasis. The cargo of the 
exosomes is enriched in non-coding RNAs, including long non-coding 
RNAs [12]. LncRNAs is a very heterogeneous group that have been 
shown to play a relevant role in tumor development and metastasis 
althought most of them have not been functionally characterized yet 
[13]. Their high specificity and the fact that they can be found inside 
tumor released exosomes make them an interesting source of bio-
markers. Uptodate few exosomal lncRNAs have been related to tumor 
prognosis [14]. Some examples in NSCLC includes MALAT1 or 
lincRNA-p21. High levels of exosomal MALAT1 were related to 
increased cell proliferation and increased migration [15] and high 
exosomal lincRNAp21 levels were related to shorter time to relapse 
(TTR) and shorter (OS) through angiogenesis regulation [16]. 
HOTTIP is an oncogenic lncRNA related to HOXA locus [17] that has 
been related to patient prognosis in several tumors [18]. In a previous 
work of our group, we showed that higher tumor HOTTIP levels corre-
lated with shorter TTR and OS in early stage NSCLC patients [19]. In this 
line, we decided to perform a pilot study to evaluate whether EV 
HOTTIP levels could be used as prognostic biomarker. We hypothesized 
that lung tumors, which overexpress HOTTIP lncRNA, could generate 
and release small EV charged with lncRNA HOTTIP and their analysis 
and quantification in peripheral blood could serve to identify patients at 
high risk of relapse after surgery and to monitorize minimal residual 
disease for early detection of postoperative recurrence of NSCLC. 
Materials and methods 
Samples 
Fifty-two serial blood samples (4 mL in EDTA tube) from peripheral 
vein were obtained before and after surgery at different times to predict 
relapse. The time points used after surgery coincided with the post-
surgical follow up visits of each patient, which also depends on tumor 
stage. In all patients at least pre-surgery and first post-surgery sample 
are available before relapse. Plasma obtained by centrifugation was 
stored at − 80 ◦C until processing. Written informed consent was ob-
tained from each participant in accordance with the Declaration of 
Helsinki and the study was approved by the Clinical Research Ethics 
Committee of the Hospital Clínic de Barcelona (project approval number 
HCB/2017/1052). 
Extracellular vesicle isolation, RNA extraction and gene expression 
analysis 
EVs from patient samples were isolated and characterized as previ-
ously described [19,20]using 200 μL of plasma and ultracentrifugation 
technique in a Sorvall MX Plus Micro-Ultracentrifuge with the S140AT 
rotor. Briefly, plasma samples were defrosted on ice and to eliminate 
potential cellular debris 3 sequential centrifugation steps at 4 ◦C were 
performed: 1) 300 G 5 min; 2) 2500 G 20 min; and 3) 10,000 G 30 min. 
The pellets obtained after each centrifugation step were discarded. Next, 
the samples were subjected to ultracentrifugation at 100,000 G for 2 h. 
Then the pellet was washed with DPBS and ultracentrifuged again at 
100,000 G for 1 h. After this step, the supernatant was discarded and the 
pellet was resuspended with 750 μl of Qiazol (Qiagen) supplemented 
with MS2 RNA (Roche) for RNA isolation. Once resuspended, RNA 
extraction was completed using miRNAeasy mini kit (Qiagen) according 
to the manufacturer’s instructions. The High-Capacity cDNA Reverse 
Transcription Kit® (Applied Biosystems) was used to obtain cDNA using 
250 ng of total RNA. Relative expression was determined by real-time 
PCR using the 7500 Real Time PCR device (Applied Biosystems). Taq-
Man assays (Life Technologies) were used to quantify HOTTIP 
(Hs00955374_s1) levels in a 7500 Real Time PCR device (Applied Bio-
systems). 18S (Hs99999901_s1) was used as endogenous control and 
relative quantification was calculated using 2− ΔΔCt. 
Statistical analyses 
TTR was defined as the time from surgery to recurrence or last 
follow-up. OS was defined as the time from surgery to the date of death 
by any cause or last follow-up. Kaplan-Meier curves for TTR and OS were 
generated and compared by means of a log-rank test. All factors with p <
0.1 in the univariate analysis were included in the Cox multivariate 
regression analyses for TTR and OS. Paired or non-paired t-tests were 
used for comparisons between two groups and ANOVA for more than 2 
groups comparisons. All statistical analyses were performed using 
GraphPad Prism 8.4.3, PASW Statistics 18 (SPSS Inc.) and R v2.8.1. 
Results 
Patients 
The study included 18 stage I-IIIa NSCLC patients who underwent 
complete surgical resection in Hospital Clínic of Barcelona. The mean 
patient age was 65 years (range, 39–83) and 83.3% of patients were 
male. Six of the seven stage III patients where diagnosed as stage III after 
surgery when lymph nodes where studied by the pathologist and for this 
reason only one stage III received neoadjuvant treatment (P11). Eleven 
patients (61.1%) had received adjuvant chemotherapy after surgery. 
Median follow-up time was 55.37 months (IQR: 53.03–65.70), during 
follow-up, a total of seven patients relapsed, six of whom died. The main 
clinic-pathological characteristics of the patients are summarized in 
Table 1 and the survival and status at last follow up for each patient is 
included in Table 2. 
Tracking EV HOTTIP levels in serial plasma samples predicts relapse 
We investigated the potential utility of HOTTIP quantification in EV 
for detecting minimal residual disease and relapse prediction. Fifty-two 
samples from 18 patients were studied including at least the presurgical 
blood sample and the sample obtained at the first postsurgical visit be-
tween 3 and 6 months depending on the disease stage (Figs. 1,2). In the 
eleven patients that not relapsed after surgery (Fig. 1), we observed that 
HOTTIP levels in the first post-surgical sample was decreased in 10 of 
11. Two of the previous patients (P7 and P18) showed a very small 
reduction in the EV-HOTTIP levels in the first follow-up visit after sur-
gery (at 3 months), but both showed an important reduction in the 
second follow-up visit (at 6 and at 11 months, respectively). The unique 
patient that increased their levels (P1, at 6 months), showed an impor-
tant reduction in the next follow-up visit (at 12 months). One patient 
(P5) despite showed a reduction in the first postsurgical sample (at 5 
months), showed an important upregulation in the 2nd follow-up visit 
(at 9 months). Although this patient not relapsed for the lung tumor, he/ 
she was diagnosed with an Hepatocellular carcinoma 11 months after 
surgery and died from this new tumor 22 months after lung cancer 
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resection. 
Seven patients relapsed after surgery (Fig. 2). In all patients we 
observed an upregulation of HOTTIP levels in comparison with the 
presurgical sample in the sample obtained previous to the diagnosis of 
the relapse. In patients with more than one sample after surgery (P9, P10 
and P13) we observed that the levels increased progressively. In patient 
4 (P4), the levels were downregulated in the first follow-up visit after 
surgery (at 3 months), but increased at 6 months and the relapse was 
diagnosed 8 months after surgery. 
Relapse prediction based on evaluation of EV HOTTIP levels on the first 
postsurgical sample 
Since in all patients we had at least the presurgical the first post-
surgical follow-up sample, we decided to analyze if with this data we 
were able to predict relapse. We worked with the EV HOTTIP levels in 
the first postsurgical sample calibrated to each patient basal presurgical 
sample (from now on EV HOTTIP in 1st postsurgical sample). We 
observed that EV HOTTIP in 1st postsurgical sample were significantly 
higher in relapsed than in non-relapsed patients (p = 0.002, Fig. 3). 
Then we decided to evaluate whether EV HOTTIP in 1st postsurgical 
sample could be used to predict relapse after surgery using ROC curves 
analysis. The area under the curve (AUC) value according EV HOTTIP in 
1st postsurgical sample was 0.935 (95% confidence interval (CI), 
0.819–1.0, p = 0.002) with a sensitivity of 87.5% and specificity of 
90.9% in distinguishing patients who relapse after surgery in its best 
threshold (0.0552) (Fig. 4). Using 0.0552 as a threshold, the negative 
predictive value was 90.9%, and the positive predictive value was 
85.7%. 
Prognostic impact of EV HOTTIP levels in 1st postsurgical sample 
To analyze the prognostic impact of the EV HOTTIP levels in 1st 
postsurgical sample we divided the patients in two groups according the 
observed trend in the EV HOTTIP expression in the 1st postsurgical 
sample in comparsion with its own presurgical sample. Then we grouped 
patients in patients which expression increased and patients with non 
increased expression. Using this classification, we observed that patients 
where EV HOTTIP levels increased after surgery had shorter TTR (9.7 
months vs not reached; p = 0.001) and shorter OS (13.1 months vs not 
reached; p = 0.012) than patients that had no change or reduced their 
levels (Fig. 5). 
Multivariate analysis showed that EV HOTTIP in 1st postsurgical sample is 
an independent prognsotic marker of TTR and OS 
EV HOTTIP levels in 1st postsurgical sample, disease stage and 
adjuvant treatment, were included in the multivariate analyses. High EV 
HOTTIP levels in 1st postsurgical sample emerged as an independent 
prognostic marker for shorter TTR (Hazard ratio [HR]: 6.621; 95% 
confidence interval [CI]: 1.599–27.415; p = 0.009) and shorter OS (HR: 
6.586; 95% CI: 1.331–32.595; p = 0.021). Adjuvant treatment admin-
istration emerged also an independent factor for OS (HR: 0.106; 95% CI: 
0.018–0.641; p = 0.015). 
Discussion 
Postoperative recurrence is the major factor affecting the long-term 
survival of resected NSCLC patients [21]. The postoperative follow-up 
should ideally include the analysis of molecular markers enhancing 
early detection of recurrence and metastasis allowing the identification 
of patients candidates for an aggressive treatment strategy [22,23]. In 
the context of stage I NSCLC patients, who not receive adjuvant treat-
ment after surgery this could means to detect patients with a more 
Table 1 
Summary of the main clinical characteristics of the 18 NSCLC patients included 
in the study. ECOG PS, Eastern Cooperative Oncology Group performance status.  
Characteristics Value N=18 N (%) 
Sex Male 15 (83.3) 
Female 3 (16.7) 
Age, years Mean (Range) 65 (39-83) 
<=65 10 (55.6) 
>65 8 (44.4) 
ECOG PS 0 1 (5.6) 
1 17 (94.4) 
pT 1 5 (27.8) 
2 11 (61.1) 
3 2 (11.1) 
Lymph node status (pN) Negative 7 (38.9) 
Positive 11 (61.1) 
pTNM Stage I 5 (27.8) 
II 6 (33.3) 
III 7 (38.9) 
Histology Adenocarcinoma 7 (38.9) 
Squamous cell carcinoma 11 (61.1) 
Smoking history Current smoker 10 (55.6) 
Former smoker 8 (44.4) 
Type of surgery Lobectomy 15 (83.3) 
Pneumonectomy 1(5.6) 
Bilobectomy 2 (11.1) 
Adjuvant treatment No 7 (38.9) 
Yes 11 (61.1) 
Relapse No 11 (61.1) 
Yes 7 (38.9)  
Table 2 
Stage, treatment received and survival and status at last follow up for each patient included in the study.  
Patient pTNM Neoadjuvant Treatment (Yes/No) Adjuvant Treatment Relapse TTR (months) Last follow-up Status Follow-up (months) 
P1 I No No No – Alive 50.03 
P2 III No Chemotherapy No – Alive 50.07 
P3 III No Chemotherapy + Radiotherapy No – Alive 66.87 
P4 I No No Yes 8.33 Death 28.63 
P5 I No No No – Alive 22.80 
P6 II No Chemotherapy Yes 33.33 Death 43,93 
P7 II No No No – Alive 55.37 
P8 II No Chemotherapy No – Alive 55.43 
P9 III No Chemotherapy + Radiotherapy Yes 7.07 Death 13.10 
P10 III No No Yes 9.70 Death 11.83 
P11 III Yes Radiotherapy Yes 5.17 Death 5.60 
P12 II No Chemotherapy No – Alive 65.00 
P13 II No No Yes 18.93 Alive 53.73 
P14 II No Chemotherapy No – Alive 53.03 
P15 II No Chemotherapy No – Alive 55.43 
P16 I No No Yes 3.13 Death 5.53 
P17 III No Chemotherapy + Radiotherapy No – Alive 60.33 
P18 III No Chemotherapy No – Alive 70.53  
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Fig. 1. EV HOTTIP tracking in 11 patients who were disease-free after surgery and that not showed relapse at last follow-up. CT, chemotherapy; CRT, chemo-
radiotherapy; M, months; HCC, hepatocellular carcinoma. 
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Fig. 2. EV HOTTIP levels tracking in 7 patients who were disease-free after surgery but relapsed some months later. CT, chemotherapy; CRT, chemoradiotherapy; M, 
months; Neo CRT, neoadjuvant chemoradiotherapy. 
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aggressive disease that could benefit from adjuvant chemotherapy 
treatment. However, at present, effective testing methods for post-
operative follow-up remain to be established, and guidelines recom-
mended by major organizations in western countries differ considerably 
[22,23]. The aim of our study was to find an effective and non-invasive 
method to predict and monitor postoperative recurrence by examining 
EV HOTTIP levels in resected NSCLC patients treated and followed in 
our center after curative surgery. 
To our knowledge, we have provided the first evidence that EV 
HOTTIP levels are associated with NSCLC recurrence and it is a useful 
tool to monitor patient progression after surgery. We observed that 
patients that relapsed some months after surgery displayed an increase 
of the postsurgical EV HOTTIP levels in comparison with presurgical 
basal levels. In the patients with several samples available at different 
times after surgery and before clinical detection of relapse, we could 
observe an ascendent trend in the EV HOTTIP levels, which indicated its 
potential utility for monitoring disease evolution. Interestingly, we 
detected one patient (P5) that not relapsed but the increase in the EV 
HOTTIP levels were linked to the diagnosis of Hepatocellular carcinoma 
11 months after lung tumor resection. Despite of its diffciult to make 
conclusions only with one patient, we could speculate that probably EV 
HOTTIP could be used to monitor disease evolution in other 
malignancies. 
When we focused in the utility of the analysis of EV HOTTIP levels 
only in the first postsurgical sample available, which was usually be-
tween 3 and 6 months after surgery (coinciding with the patient post-
surgical follow-up visit, which is mainly depending on the patient stage), 
we observed that the detection of an increment of the expression levels 
in comparison with the basal presurgical sample was able to predict 
recurrence with high sensitivity (85.7%) and specificity (90.9%). In this 
line the patients which EV HOTTIP levels increased in the first post-
surgical sample had shorter TTR and shorter OS than patients with no 
change or with lower levels. Finally, the multivariate analysis showed 
that EV HOTTIP levels in first postsurgical sample calibrated to pre-
surgical sample is an independent marker for both TTR and OS. 
Although to our knowledge no other studies are available analyzing in 
serial blood samples the clinical potential of tracking EV HOTTIP levels, 
it has been shown in other tumors that EV HOTTIP levels can act as 
diagnostic and prognostic biomarker. In gastric cancer high levels of EV 
HOTTIP correlated with poor OS and had a higher diagnostic capability 
than traditional clinical markers such as CEA levels [24]. In contrast, in 
colorectal cancer lower EV HOTTIP levels were associated with 
decreased OS, but in the same line they observed that low tumor levels 
were also related to worse postsurgical prognosis of these patients [25]. 
Interestingly, Wu F. et al. [26] showed that HOTTIP levels can also be 
detected in EV purified from bronquioalveolar lavage from NSCLC pa-
tients, which indicates that the analysis of HOTTIP levels in this type of 
samples could also have utility for diagnosis or prognosis analysis in 
NSCLC patients, but the authors not analyzed specifically the utility of 
HOTTIP as biomarker is this medium. 
The role of HOTTIP in tumor cells have been widely studied showing 
that HOTTIP acts mainly as an oncogene in the majority of cancers [18]. 
In most tumors HOTTIP is upregulated in comparison to its normal 
counterpart and its primary oncogenic role is related to modulation of 
HOXA genes expression through histone methylation [27]. Moreover, it 
Fig. 3. Violin plot showing EV HOTTIP levels in 1st postsurgical sample in 
relapsed and non-relapsed patients. **p < 0.01. 
Fig. 4. ROC curve analysis of EV HOTTIP ratio values predicting relapse after 
surgery in NSCLC patients. The best threshold identified was 0.0552 which was 
rounded to 0.1 in the graph. 
Fig. 5. Kaplan–Meier survival analysis showing the different prognosis for TTR (A) and OS (B) between patients with increased vs not increased levels of EV HOTTIP 
after surgery. 
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has been described that HOTTIP levels are related to smoking history in 
tumor tissue [19]. In the present work all included patients were either 
current smokers (n = 10) or former smokers (n = 8). We analyzed (data 
not shown) whether significant differences could be observed between 
both groups according to smoking status in both presurgical blood 
sample and in the first post-surgical sample, and no significant differ-
ences were observed. Taking in account this results and the fact that in 
our previous paper we did not observed significant differences between 
current and formers smokers, that corresponds to most of the patients in 
NSCLC, we consider that the smoking history of the patients will not 
affect the use of HOTTIP as prognostic tool. Moreover, the fact that we 
evaluated HOTTIP levels in relation to baseline sample of each patient 
(presurgical sample) we consider that we are correcting potential biases 
that could emerge in relation with the smoking history or other clinical 
characteristics of the patients. 
Additional oncogenic mechanisms have been described in different 
tumors. In NSCLC, HOTTIP has been described to promote proliferation 
and migration through HOXA13 regulation [28] and also drug resistance 
by regulation of the AKT pathway [29]. Interestingly, it has been shown 
that in NSCLC cells HOTTIP become upregulated in hypoxic conditions 
and promotes glycolysis by regulation of HMGB3 gene indirectly 
through sponging miR-615–3p [30]. In the same line, but in an 
atherosclerosis model it has been shown that HOTTIP regulated endo-
thelial cell proliferation and migration by induction of B-catenin 
expression and modulation of c-Myc pathway [31]. Taken together all 
this information we can speculate that tumor cells can modulate endo-
thelial cell behavior in hipoxic conditions by releasing EV containing 
high levels of HOTTIP and this could enhance the metastasis process. 
This potential mechanism of action have been observed previously in 
NSCLC with other EV lncRNAs such as lincRNA-p21 [16]. 
In summary, we have showed in this pilot study that EV HOTTIP can 
be used as a liquid biopsy biomarker to monitor disease recurrence after 
NSCLC surgery. Its analysis in serial samples after surgery could be of 
potential utility to predict whether patients will develop cancer recur-
rence or metastasis within one year after surgery. However, the present 
study has several limitations including the low number of patients 
enrolled in the study or the fact that relative quantification has been 
performed for HOTTIP analysis. In relation to the low number of pa-
tients, a prospective analysis including more patients may be warranted 
to validate the potential utility of this follow-up biomarker. The most 
recent clinical guidelines analyzing the available tools for NSCLC sur-
veillance after curative surgery, not recommends the use of blood bio-
markers because not enough experimental evidences and studies in large 
cohorts support their utility, and therefore the image techniques are yet 
the most extended method for monitoring recurrence [32]. Blood bio-
markers are only recommended in the context of clinical trials indicating 
that we are far from translate from bench to clinic the use of these type of 
biomarkers, but the validation in additional cohorts of results like the 
ones included in the present paper can be the first step to accelerate the 
inclusion of blood biomarkers in routine clinical use. By another hand, 
the other limitation of the present study was related to the quantification 
method used. The use of absolute quantification without the use of a 
reference gene may enhance the clinical use of HOTTIP or other iden-
tified EV-associated lncRNAs in the clinic. The more extensive use of 
digital PCR could solve this limitation in a forseable future. Although, 
these limitations, we think that the finding are significative since no 
prior research have been performed in this topic and opens a door to 
further analyze the potential utility for monitoring minimal residual 
disesease in resected NSCLC patients using EV lncRNAs. Functional 
studies to fully understand the role of EV HOTTIP will also increase the 
validity of this new potential biomarker. We believe that in the near 
future we will see not only the use of EV HOTTIP levels as recurrence 
tracking marker in NSCLC, but also in other tumors and the identifica-
tion of more EV lncRNAs with clinical utility. 
Conclusions 
In conclusion, we identified EV HOTTIP as a biomarker for predict-
ing postoperative recurrence in patients with NSCLC. Our study has 
shown that when the expression levels of EV HOTTIP increase during the 
postsurgical follow up, the patient is highly likely to have cancer 
recurrence or metastasis. Therefore, EV HOTTIP should be considered as 
a promising key factor in predicting postoperative risk of NSCLC 
recurrence. Considering the diversity of exosome cargos and their 
important role, more studies should be carried out with these molecules 
in the future to detect the risk of recurrence after NSCLC surgery. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Funding 
This work was supported by grants from the Ministry of Economy, 
Industry, and Competition, Agencia Estatal de Investigación co-financed 
with the European Union FEDER funds SAF2017-88606-P (AEI/FEDER, 
UE). None of the funding bodies had any role in the design of the study 
and collection, analysis, and interpretation of data, or in writing the 
manuscript. 
Author Contributions 
Conceptualization, Bing Han, Mariano Monzo and Alfons Navarro; 
Data curation, Ramón María Marrades, Nuria Viñolas, Laureano Molins, 
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